Filing Details

Accession Number:
0001209191-10-008130
Form Type:
4
Zero Holdings:
No
Publication Time:
2010-02-10 12:00:00
Reporting Period:
2010-02-08
Filing Date:
2010-02-10
Accepted Time:
2010-02-10 16:30:42
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1103390 Ardea Biosciences Inc. RDEA Pharmaceutical Preparations (2834) 943200380
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1384243 D Barry Quart 4939 Directors Place
San Diego CA 92121
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2010-02-08 25,000 $3.90 46,515 No 4 M Direct
Common Stock Disposition 2010-02-08 25,000 $14.57 21,515 No 4 S Direct
Common Stock Acquisiton 2010-02-08 20,000 $3.90 41,515 No 4 M Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2010-02-08 25,000 $0.00 25,000 $3.90
Common Stock Employee Stock Option (Right to Buy) Disposition 2010-02-08 20,000 $0.00 20,000 $3.90
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
255,000 2016-12-20 No 4 M Direct
235,000 2016-12-20 No 4 M Direct
Footnotes
  1. The stock option exercise and sale of 25,000 shares of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of June 11, 2009.
  2. The range of sales prices received was $14.5201 to $14.73. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.
  3. 12.5% of the shares subject to the stock option vested and became exercisable on June 21, 2007, and 12.5% of the shares subject to the stock option vested and became exercisable on December 21, 2007. The remaining shares vest in equal monthly installments over the following 3 years.